Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease.
about
α-Synuclein genetic variants predict faster motor symptom progression in idiopathic Parkinson diseaseMitochondrial targeting of electron scavenging antioxidants: regulation of selective oxidation vs random chain reactionsVitamin E for Alzheimer's dementia and mild cognitive impairmentVitamin E for Alzheimer's disease and mild cognitive impairmentMonoamine oxidase B inhibitors for early Parkinson's diseaseNeuroprotection by pharmacologic blockade of the GAPDH death cascadeMonoamine oxidase type B inhibitors in early Parkinson's disease: meta-analysis of 17 randomised trials involving 3525 patientsDose linearity study of selegiline pharmacokinetics after oral administration: evidence for strong drug interaction with female sex steroidsN-acetylcysteine (NAC) in neurological disorders: mechanisms of action and therapeutic opportunitiesMAO-inhibitors in Parkinson's DiseaseThe recommendations of Chinese Parkinson's disease and movement disorder society consensus on therapeutic management of Parkinson's diseaseNeuroprotective and Therapeutic Strategies against Parkinson's Disease: Recent PerspectivesNutraceuticals in Parkinson's DiseaseThe Role of Oxidative Stress in Neurodegenerative DiseasesOxidative Stress in Neurodegenerative DiseasesA review of clinical trial designs used to detect a disease-modifying effect of drug therapy in Alzheimer's disease and Parkinson's diseaseInhibitors of MAO-A and MAO-B in Psychiatry and NeurologyAnti-Oxidants in Parkinson's Disease Therapy: A Critical Point of ViewDietary factors in the etiology of Parkinson's disease.Clinical pharmacology of rasagiline: a novel, second-generation propargylamine for the treatment of Parkinson diseaseGlyceraldehyde-3-phosphate dehydrogenase, the putative target of the antiapoptotic compounds CGP 3466 and R-(-)-deprenylFuzzy Decision Making Approach to Identify Optimum Enzyme Targets and Drug Dosage for Remedying Presynaptic Dopamine DeficiencyMitochondrial therapy for Parkinson's disease: neuroprotective pharmaconutrition may be disease-modifyingMechanisms for alternative treatments in Parkinson's disease: acupuncture, tai chi, and other treatments.A review of the clinical evidence for complementary and alternative therapies in Parkinson's disease.Self-reported efficacy of cannabis and other complementary medicine modalities by Parkinson's disease patients in colorado.Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progressionMonitoring of 30 marker candidates in early Parkinson disease as progression markers.Entacapone.Authors' response to Marras and Oakes, 'Piecing together the puzzle of progression and mortality in Parkinson's disease'.Pharmacologic management of Alzheimer disease, Part II: Antioxidants, antihypertensives, and ergoloid derivatives.Complementary and alternative medicines for Alzheimer's disease.Treatment of early Parkinson's disease.Medical and surgical treatment of Parkinson's disease. Strategies to slow symptom progression and improve quality of life.Multiple antioxidants in the prevention and treatment of Parkinson's disease.A novel design of a Phase III trial of isradipine in early Parkinson disease (STEADY-PD III).The challenge of managing mild Parkinson's disease.Effects of combined MAO-B inhibitors and levodopa vs. monotherapy in Parkinson's disease.CSF xanthine, homovanillic acid, and their ratio as biomarkers of Parkinson's disease.Urate as a predictor of the rate of clinical decline in Parkinson disease.
P2860
Q21090919-F619BC80-602B-4A4C-BD53-4670F170EA14Q23923177-E065725D-331A-473B-AD1A-93E8E2AB1000Q24202844-F00516D9-E420-4530-B9D3-CAD10917CC5CQ24241955-4CA75095-460F-47A2-BA68-44B3AFB0DBFDQ24246514-64C7185A-E46D-4F0A-BF5E-CD938E25933AQ24545207-E4FE3BFA-B253-4FC7-B58C-1AD30CA19C88Q24561822-D1C3A24A-CBFE-47B6-BA6F-C72F25C0A602Q24564970-EED51B1F-F210-454C-AF90-8F7A71A557D3Q24568289-2C34E661-C9A4-4833-9E3D-112279054FECQ24629770-6B03914F-C2C0-4CF2-B8BB-9F4D285221C5Q26745661-8E7ADFF5-C4BD-4F39-B7A0-2029AF396AEDQ26747508-309DE0DA-B504-4E22-8704-F63BB7779EF2Q26752769-760CA7E2-7C41-4F43-8BDB-3FF3C6EA761CQ26771758-3D8EE18D-3A84-4A2C-8395-212C60E51AB7Q26801239-C0B2D191-9410-431F-A4A3-DBE8850B5F95Q27311651-9F726ACC-2371-424A-80BB-1F08E7A23666Q28069609-728871F0-8606-4EB4-AB72-748DBD12A12FQ28084254-BA66D218-BFA1-4719-91DA-64F7BD05E080Q28085390-8F00B872-181D-467A-9CD0-01696CB1AA64Q28262497-DBC01C1F-7E18-484C-B916-2EC241FFFCD9Q28263664-4F7EF51A-B90D-4EAC-AFF7-3E7A937E148BQ28554723-D4220A65-8430-4BC0-BACD-A30B5CE7D6A4Q28732683-CEA3F1BC-8E38-41C2-893C-926C23715569Q30361677-A3C1C75B-1724-466C-9065-2043202623CCQ30365907-A379DB5E-28BE-4662-86A5-63CBCF1A0190Q30373216-93369289-FFA0-403A-9458-0DE9A02C7F0FQ30501271-9CEFB02D-F6A5-4C18-8406-34DD4EB52857Q30783504-834180EF-D912-4AD7-871E-FE8E9DB42E16Q31440112-078C5B73-2AF9-452B-BB73-B60829FBCB99Q33354359-A61EF8FF-DA83-4524-B5DD-317E9AA30755Q33543113-F872EC2A-D8AD-445D-B452-A47A426C6B9FQ33609573-39CB183E-4D5B-4D2A-AAAE-82FBDBC4C4BAQ33714133-4627C852-BF89-4873-9FBC-1E8C66317D96Q33716752-93CA6ECB-806F-45FF-8316-ABEBE9938B70Q33746725-5F6F14D0-C168-49CA-9C3A-230E45E30C57Q33753874-147F298F-6A21-48DF-8032-E9CBD82FB24DQ33821330-E1F1C6C4-79CE-47BF-BD10-574E7E5E8F6DQ33950517-FE156A11-9440-4F1D-B04C-15CB9047F65EQ33994583-FDDBDF5B-63E9-4A09-A81E-81BFD2FF65DFQ34019732-E1CADFFD-AEA5-4E01-A0E4-C97465A28A53
P2860
Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease.
description
1993 nî lūn-bûn
@nan
1993 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
1993 թվականի հունվարին հրատարակված գիտական հոդված
@hy
1993年の論文
@ja
1993年論文
@yue
1993年論文
@zh-hant
1993年論文
@zh-hk
1993年論文
@zh-mo
1993年論文
@zh-tw
1993年论文
@wuu
name
Effects of tocopherol and depr ...... in early Parkinson's disease.
@ast
Effects of tocopherol and depr ...... in early Parkinson's disease.
@en
Effects of tocopherol and depr ...... in early Parkinson's disease.
@nl
type
label
Effects of tocopherol and depr ...... in early Parkinson's disease.
@ast
Effects of tocopherol and depr ...... in early Parkinson's disease.
@en
Effects of tocopherol and depr ...... in early Parkinson's disease.
@nl
prefLabel
Effects of tocopherol and depr ...... in early Parkinson's disease.
@ast
Effects of tocopherol and depr ...... in early Parkinson's disease.
@en
Effects of tocopherol and depr ...... in early Parkinson's disease.
@nl
P1476
Effects of tocopherol and depr ...... in early Parkinson's disease.
@en
P2093
Parkinson Study Group
P304
P356
10.1056/NEJM199301213280305
P407
P577
1993-01-01T00:00:00Z